Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 4Active not recruiting 2Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Renal Cell 20Neoplasm Metastasis 12Prostatic Neoplasms 11Neoplasms 8Carcinoma, Hepatocellular 8Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 5Colorectal Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Liver Neoplasms 3Carcinoma, Transitional Cell 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Recurrence 2Pheochromocytoma 2Paraganglioma 2Neuroendocrine Tumors 2Multiple Myeloma 2Melanoma 2Kidney Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Medullary 2Carcinoid Tumor 2Brain Neoplasms 2Adenocarcinoma 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urothelial Cancer 1Urethral Neoplasms 1

Interventions

Cyclophosphamide 10Irinotecan 8Melphalan 7Vincristine 6Temozolomide 6Doxorubicin 6Busulfan 6Topotecan 5Granulocyte Colony-Stimulating Factor 5Gemcitabine 5Ifosfamide 4Filgrastim 4Etoposide 4Albumin-Bound Paclitaxel 4Trabectedin 3Sirolimus 3Nivolumab 3130-nm albumin-bound paclitaxel 3pegfilgrastim 2olaparib 2fludarabine phosphate 2fludarabine 2eribulin 2cixutumumab 2abemaciclib 2X-Rays 2Radiotherapy, Intensity-Modulated 2Peripheral Blood Stem Cell Transplantation 2Magnetic Resonance Spectroscopy 2Granulocyte-Macrophage Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Sarcoma, Ewing × cabozantinib × Clear all
NCT04661852 2023-02-15

Cabozantinib With Topotecan-Cyclophosphamide

Dana-Farber Cancer Institute

Phase 1 Completed
12 enrolled
Sarcoma

Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡